Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in Non-segmental Vitiligo
2024-515642-17-00Phase 2Withdrawn
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pioglitazone in Vitiligo, sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoints: Proportion of subjects achieving VASI-50 at Week 32, Percent change from baseline in VASI and 6 more. Planned start Oct 2024; status: withdrawn.
02
Drugs
pioglitazone
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2024-515642-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515642-17-00.